Search Results 541-550 of 18018 for Alopecia

  1. A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma - Mayo Clinic

    ... alopecia and decreased tendon reflex and to ≤ Grade 1 for all other effects at the time of enrollment, unless otherwise noted. Consult with the Lilly ...

  2. Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery - Mayo Clinic

    ... alopecia and grade 2 neuropathy are acceptable; Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; Patients must be ...

  3. A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer - Mayo Clinic

    Grade > 1 alopecia or fatigue is permitted. Participants must allow a ... alopecia) not requiring systemic treatment, or conditions not expected to ...

  4. Addison's disease - Symptoms and causes - Mayo Clinic

    Learn about this rare but serious condition of the adrenal glands that's treated by replacing hormones the body needs.

  5. Ph 1b Study to Evaluate GSK2110183 in Combination with Bortezomib and Dexamethasone in Subjects with Multiple Myeloma - Mayo Clinic

    Unresolved toxicity (except alopecia) ≥ Grade 2 National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 [NCI ...

  6. Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction - Mayo Clinic

    ... alopecia; Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; Note: patients not on antiretroviral ...

  7. Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer - Mayo Clinic

    ... alopecia, ototoxicity and neuropathy. Patients must not be receiving any other investigational anti-cancer agents while on study. Patients must not have ...

  8. MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer - Mayo Clinic

    Failure to recover to ≤Grade 1 from acute, reversible effects of prior chemotherapy, excluding alopecia regardless of interval since last treatment. NOTE ...

  9. A Study to Evaluate the Effectiveness, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera - Mayo Clinic

    Clinically significant toxicity (other than alopecia) from prior therapy that has not resolved to Grade ≤ 1 (according to the NCI CTCAE, v4.0) prior to Day 1 ...

  10. Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer - Mayo Clinic

    ... alopecia and sensory neuropathy grade ≤ 2 is acceptable. Known severe (grade ≥ 3 NCI-CTCAE v5.0) hypersensitivity reactions to monoclonal antibodies, or ...